Apr 14, 2020 / 12:00PM GMT
Operator
Good morning, and welcome to the MEI Pharma conference call for the ME-401 Global License, Development and Commercialization Agreement. Please be advised that the call is being recorded at the company's request.
At this time, I would like to turn the call over to David Walsey, MEI's Vice President, Investor Relations and Corporate Communications. Please proceed.
David A. Walsey - MEI Pharma, Inc. - VP of IR & Corporate Communications
Thank you. Good morning, everyone, and thank you for joining us.
Earlier today, we announced that MEI Pharma and Kyowa Kirin Co., Ltd. entered into a global license, development and commercialization agreement to further develop and commercialize MEI's ME-401. On today's call, we will provide an overview of and commentary on the agreement. We will then open the call to your questions.
Before we get started, I want to call your attention to the fact that this conference call may contain certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities
MEI Pharma, Inc. - Special Call Transcript
Apr 14, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers